Business
Hoth Therapeutics Announces Positive, Statistically Significant Proof-of-Concept Preclinical Data on its Therapeutic for Cutaneous Lupus Erythematosus (CLE), a Chronic Autoimmune Skin Disease
The study was conducted by Jackson Laboratory in partnership with Zylö Therapeutics The animal study supports that this drug candidate has the potential to be
About this update from Hoth Therapeutics, Inc.
[{"type":"text","content":"The study was conducted by Jackson Laboratory in partnership with Zylö Therapeutics\n The animal study supports that this drug candidate has the potential to be an effective treatment for cutaneous manifestations of lupus, a significant unmet medical need\n\n\nNEW YORK, Nov. 3, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced positive, statistically significant proof-of-concept preclinical data on its therapeutic HT-005 for the treatment of Cutaneous Lupus Erythematosus (CLE), a chronic autoimmune skin disease. \n\n \n \n \n \n \n \n\n \nThe study conducted by Jackson Laboratory in partnership with Zylö Therapeutics using a CLE mouse model demonstrated a significant reduction in skin plaque severity after treatment with HT-005-loaded topical Z-pods™ compared to untreated control mice. The skin severity scoring was based on a semi-quantitative measurement scale of erythema, thickness, scaling, and alopecia measured on the scapula, head, and overall composite score. The study was conducted over the period of 10 weeks and significant reduction of plaque severity in the overall composite score was observed within 3 weeks of treatment and maintained through the entire 10 week treatment cycle, supporting that the therapeutic response is sustained. \n\"Our final preclinical proof-of-concept data set provides us with optimism in our topical drug candidate for a high unmet need indication, CLE,\" stated, Robb Knie, Chairman and CEO of Hoth Therapeutics. \"We look forward to working with our partner, Zylö Therapeutics, on the next phase of development of this promising therapeutic.\"\nAbout Hoth Therapeutics, Inc.Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new generation therapies for dermatological disorders. Hoth's pipeline has the potential to improve the quality of life for patients suffering from indications including atopic dermatitis, chronic wounds, psoriasis, asthma and acne. Hoth has also recently entered into two different agreements to further the development of two different vaccine prospects to prevent or treat COVID-19. To learn more, please visit www.hoththerapeutics.com.\nForward-Looking StatementThis press release includes forward-looking statements based upon Hoth's current expectations which may constitute forward-l...